FGL vs Pinealon
A side-by-side research comparison of FGL and Pinealon across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | Pinealon |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | Pinealon (Glu-Asp-Arg) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | As a peptide bioregulator it is proposed to penetrate cells and interact with DNA to modulate gene expression in neural tissue, reducing oxidative damage and supporting neuronal survival and protein synthesis. |
| Molecular weight | ~1,800 Da | ~418 Da |
| Half-life | 4-8 hours | Short (small peptide, rapidly metabolized) |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | Injectable in research; intranasal also used |
| Typical dose | 1-5 mg/kg (research) | ~5-10 mg per course day (research) |
| Frequency | Daily or every other day | Daily during a short course |
| Route | Subcutaneous | Subcutaneous or intranasal |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
Pinealon reported benefits
- Neuroprotective and antioxidant effects (research)
- Supports cognition under stress/aging
- May support healthy sleep-wake regulation
- Short-course bioregulator profile
Related comparisons
Research and educational reference only. Not medical advice.